Loading
Zemcelpro is a laboratory-expanded umbilical cord blood transplant for adults with blood cancers who need a donor stem cell transplant but have no suitable matched donor; expanding the cells lets a single small cord blood unit be enough.
Dorocubicel was authorised by the European Commission in August 2025 as an advanced therapy medicinal product for adults with haematological malignancies requiring allogeneic haematopoietic stem cell transplantation after myeloablative conditioning for whom no other suitable donor cells are available. It consists of the CD34-positive fraction of a single cord blood unit expanded with UM171, a pyrimidoindole agonist of stem cell self-renewal discovered at Universite de Montreal, together with the unexpanded CD34-negative cells. Phase 2 studies showed faster neutrophil engraftment than historical unmanipulated cord blood and low rates of severe chronic graft-versus-host disease, addressing the slow engraftment that limited cord blood transplants in adults. It is not approved in the US. Risks are those of allogeneic transplantation: infection, graft failure and graft-versus-host disease. Developed by ExCellThera.
CD34-positive cord blood cells expanded ex vivo for seven days with the small molecule UM171, which preserves haematopoietic stem cell self-renewal, co-infused with the non-expanded CD34-negative fraction to reconstitute haematopoiesis after myeloablative conditioning.
1.Dorocubicel (UM171-expanded cord blood) slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| EU | 2025 | Adults with haematological malignancies requiring allogeneic HSCT after myeloablative conditioning with no other suitable donor cells |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Dorocubicel" OR ABSTRACT:"Dorocubicel" OR TITLE:"UM171-expanded cord blood" OR ABSTRACT:"UM171-expanded cord blood" OR TITLE:"Zemcelpro" OR ABSTRACT:"Zemcelpro" OR TITLE:"UM171 cell therapy" OR ABSTRACT:"UM171 cell therapy" OR TITLE:"ECT-001" OR ABSTRACT:"ECT-001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Dorocubicel (UM171-expanded cord blood), not a curated reading list.
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic (off-the-shelf) cell therapy, Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.